desipramine has been researched along with Cortical Lewy Body Disease in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Kopin, IJ | 1 |
| Sharabi, Y | 1 |
1 other study available for desipramine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Cytosol; Desipramine; Dopamine; Female; Fluori | 2011 |